secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-150830
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology Q1 net loss $12.9M; Taiho deal adds $275M, extends cash runway through 2026
--------------------------------------------------------------------------------

- Cash and investments $410M at March 31, 2022; $685M including $275M Taiho upfront; runway extended to 2026.
- Net loss $12.9M vs $34.2M Q4 2021; R&D expense $24.5M, G&A $8.1M.
- CLN-081 co-development deal with Taiho: $275M upfront, up to $130M milestones, 50/50 US profit share.
- CLN-081 granted Breakthrough Therapy Designation; 41% confirmed ORR at 100mg BID; ASCO oral June 2022.
- IND filings for CLN-617 and CLN-978 on track for H1 2023; CLN-049 and CLN-619 Phase 1 dosing ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522150830/0001193125-22-150830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522150830/d696900d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-150830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer